De Laurentiis, M., Borstnar, S., Campone, M., Warner, E., Bofill, J. S., Jacot, W., … Zamagni, C. (2022). Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast Cancer Res Treat, 191(1), 223–224. https://doi.org/10.1007/s10549-021-06374-6

De Laurentiis, Michelino, Simona Borstnar, Mario Campone, Ellen Warner, Javier Salvador Bofill, William Jacot, Susan Dent, et al. “Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.” Breast Cancer Res Treat 191, no. 1 (January 2022): 223–24. https://doi.org/10.1007/s10549-021-06374-6.

De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, et al. Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast Cancer Res Treat. 2022 Jan;191(1):223–4.

De Laurentiis, Michelino, et al. “Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.” Breast Cancer Res Treat, vol. 191, no. 1, Jan. 2022, pp. 223–24. Pubmed, doi:10.1007/s10549-021-06374-6.

De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, Lu J, Ciruelos E, Azim HA, Chatterjee S, Zhou K, Wu J, Menon-Singh L, Zamagni C. Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast Cancer Res Treat. 2022 Jan;191(1):223–224.